+3 more ↓
91%
Finnrick rating
#2 of 223 Retatrutide vendors
29 of 31 classifiable tests passed
natural 94% · customers 4.7★ (6)
methodology · Purity focus
Finnrick analysis · Retatrutide

A severe Jan 2026 identity/quantity failure (0 mg, -100%) is the main concern in SRY Labs' Retatrutide evidence, alongside an early 98.75% purity miss. Later tests resumed passing purity/fill, but batch identifiers are often missing.

methodology →
vendor intelligence report
Vendor Intelligence Report: SRY Labs

We investigated who actually operates SRY Labs — corporate records, ownership trails, web infrastructure, and how its lab results break down product by product. Read the full report before you order.

28 pages5 risk factors assessed12 Jun 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Tirzepatide
$0.28
92%
35
2
Retatrutideselected
$0.50
91%
31
3
GHK-Cu
-
67%
7
4
Semaglutide
$0.55
65%
4
5
PT-141
$0.60
52%
2
6
Cagrilintide
$1.20
49%
8
7
BPC-157
$0.50
43%
7
9
TB-500
-
36%
8
10
Tesamorelin
-
32%
12
11
CJC-1295
$2.60
27%
4
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%5 Oct 2025: 88%5 Oct 2025: 89%6 Oct 2025: 89%9 Oct 2025: 90%17 Oct 2025: 90%23 Oct 2025: 91%30 Oct 2025: 91%25 Nov 2025: 91%29 Jan 2026: 88%15 Feb 2026: 89%20 Feb 2026: 90%2 Mar 2026: 90%19 Mar 2026: 90%25 Mar 2026: 91%8 Jun 2026: 91%13 Jul 2026: current 91%88%88%91%Oct 25Jul 26
Showing Retatrutide tests only
SRY Labs Retatrutide test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
8 Jun 2026Pass
Tested
lab nameView COA
25 Mar 2026Pass
Tested
lab nameView COA
19 Mar 2026Pass
Tested
lab nameView COA
2 Mar 2026Pass
Tested
lab nameView COA
20 Feb 2026Pass
Tested
lab nameView COA
15 Feb 2026Pass
Tested
lab nameView COA
29 Jan 2026Fail
Tested
lab nameView COA
25 Nov 2025Pass
Tested
lab nameView COA
30 Oct 2025Pass
Tested
lab nameView COA
23 Oct 2025Pass
Tested
lab nameView COA
1-10 of 31

About SRY Labs test results from Finnrick

SRY Labs is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 11 peptides and 121 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible SRY Labs peptides in this dataset are Tirzepatide (35 tests) and Retatrutide (31 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 121 recent tests.

Corrections
No corrections.